Clinical Trials Logo

Unresectable Stage III NSCLC clinical trials

View clinical trials related to Unresectable Stage III NSCLC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04161352 Not yet recruiting - Clinical trials for Unresectable Stage III NSCLC

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

R-helper
Start date: November 25, 2019
Phase:
Study type: Observational

The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.